特比萘芬
管理(神学)
抗真菌
重症监护医学
抗药性
抗真菌药
医学
药品
抗真菌药
抗性(生态学)
药理学
生物
伊曲康唑
皮肤病科
微生物学
政治学
生态学
政治
法学
作者
Aditya Gupta,Avantika Mann,Shruthi Polla Ravi,Tong Wang
出处
期刊:Italian journal of dermatology and venereology
[Edizioni Minerva Medica]
日期:2023-12-13
卷期号:159 (2)
被引量:2
标识
DOI:10.23736/s2784-8671.23.07694-6
摘要
Antifungal stewardship refers to the rational use of antifungal agents. Historically, in some instances, the misuse or overuse of antifungal agents has predisposed patients to an elevated risk of systemic side-effects and treatment resistance, as well as increased healthcare costs. Superficial mycoses, such as onychomycosis, are sometimes treated without any diagnostic testing and is associated with a high likelihood of self-diagnosis and self-treatment, potentially leading to the emergence of resistance against commonly used antifungals like terbinafine. Practitioners need to ensure that a proper clinical diagnosis is backed up by appropriate testing. This may include the traditional light microscopy and culture; additionally, molecular techniques (such as polymerase chain reaction, terbinafine gene mutational analysis) and antifungal susceptibility testing are considerations as appropriate. The choice of antifungal agent should be guided by what is the standard of care in the location where the clinician practices as well as more broadly state and national prescription patterns. Recently, reports of treatment resistance concerning both superficial and deep fungal infections have added another layer of difficulty to clinical practice. This review aims to explore the phenomenon of antifungal drug resistance, and highlights the importance of adopting antifungal stewardship programs. We provide an overview of treatment resistance and mechanisms of resistance reported thus far in dermatophytes. Challenges of performing antifungal susceptibility testing and therapeutic drug monitoring are discussed, as well as principles, recommendations and future directions of antifungal stewardship programs.
科研通智能强力驱动
Strongly Powered by AbleSci AI